Category: News

Charnwood Molecular has been a key sponsor of Keele University PhD student, Lucy Tunstall, during her trek across the Sahara Desert in aid of St Lukes Hospice in Winsford, Cheshire.

Charnwood Molecular - Lucy Returns

The trek covered a 50km stretch of difficult Saharan terrain, and the trip to and from the desert itself took nine hours, giving some indication of the remoteness of the trail!

Lucy’s group covered the 50 kilometres over a four day period, and in doing so raised over £25,000 for St Lukes Hospice. The group used social media to maintain a blog throughout the trek.

The expedition involved scaling endless sand dunes, battling scorching temperatures by day and sleeping out under the stars.

Lucy has now returned from the group’s base in Marrakesh and is back working and completing her PhD studies. Lucy’s work on the development of novel anti-malarials at Keele is co-funded by Charnwood Molecular.

Lucy is a keen fund raiser and this is just the latest of a series of challenges that she has undertaken to raise funds for St Lukes Hospice.

“I am most grateful to Charnwood Molecular for sponsoring me” said Lucy. “Without the company’s support, I would not have met my funding target to participate, and I am so pleased that I got to undertake this challenge”, she added.

conference1

We are attending the following events and conferences in the coming months.

Event: ELRIG Drug Discovery 2017
Date: 3-4 October 2017
Venue: Liverpool, UK
Charnwood Molecular Representative: Dr Robin Wilkes
________________________________________________________________

Event: Catalysis without Precious Metals
Date: 17 October 2017
Venue: SCI, London, UK
Charnwood Molecular Representative: Alexandre Jolibois
________________________________________________________________

Event: 2nd Fibrosis Meeting
Date: 10 November 2017
Venue:SCI, London
Charnwood Molecular Representative: Professor Steven Allin & Dr Robin Wilkes
________________________________________________________________

Event: WPC Europe
Date: 15-17 November 2017
Venue: Lisbon, Portugal
Charnwood Molecular Representative:Dr Robin Wilkes
________________________________________________________________

Event: Recent Trends and Technologies in Medicinal Chemistry towards Medicines of the Future
Date: 8 December 2017
Venue: NHLI, London
Charnwood Molecular Representative: Dr Robin Wilkes
________________________________________________________________

Event: High Potency ADCs – from discovery to the clinic
Date: 11 December 2017
Venue: Cambridge, UK
Charnwood Molecular Representative: Professor Steven Allin
________________________________________________________________

If you would like to meet any of our representatives at these events, please email:
info@charnwood-molecular.com

Charnwood Molecular received recognition as a finalist in this year’s East Midlands Chamber Business Awards in the “Small Business of the Year” category on Friday evening.

EMA awards line up altered

Photo Caption: from l to r - Dr Mike McKenzie, Paul Hughes, Dr Robin Wilkes, Professor Steven Allin, Dr David Lathbury & Dr James Hitchin.

Professor Steve Allin, Managing Director of Charnwood Molecular, was delighted with the news:
“As we approach our twentieth anniversary as a company, this nomination is testament to the hard work and commitment of the entire team, past and present, at Charnwood Molecular. In that time, and fuelled by significant expansion of our global client base, we have made significant investments into our infrastructure leading to an expansion in our provision in discovery chemistry and process research services, and this nomination recognises our collective efforts in our drive to achieving excellence in our services.”

The award – which was open to organisations employing up to 75 full-time members of staff – recognises companies that have achieved consistent growth backed by a strong financial performance.

We’re recruiting again for a variety of roles, including: Group Leaders, Medicinal and Synthetic Organic Chemists, and Process Research Chemists.

Operating from state-of-the-art research facilities in Loughborough and BioCity (Nottingham), UK, Charnwood Molecular is a leading Contract Research Organisation providing medicinal chemistry, process research and chemical development, and other synthetic chemistry services to the global pharmaceutical, biotechnology and chemical industries.

As part of an ongoing expansion to meet the rising demand for our services, we are looking to recruit a number of experienced individuals to join our project teams in a variety of roles, including: as Group Leaders, Medicinal and Synthetic Organic Chemists, and Process Research Chemists.

Candidate specification:

Ideally PhD qualified, with experience in the following areas:

• Synthetic Organic Chemistry
• Drug Discovery
• Lead Optimisation
• Process Research / Chemical Development

We would also like to hear from graduate level chemists who have several years experience in the industry.

We can offer a competitive salary and benefits, including a company pension scheme.

At Charnwood Molecular we recognise that a company’s real strengths lie in the people that it employs. Our strategy is therefore to employ the most talented chemists to bring a wealth of creative experience to our team. If you have the drive and ambition to help shape the development of a vibrant and dynamic research-led company, then we look forward to receiving your application.

To be considered for these positions please submit a detailed CV and covering letter to:

recruitment@charnwood-molecular.com

We are recruiting for a Business Development Executive to lead on our European operations.

This exciting BD Executive role requires a committed self-starter who is driven to respond proactively to business opportunities and creatively grow the CML business, specifically in Europe. The role requires excellent communication, problem-solving and influencing skills as well as the ability to work effectively as part of a small but growing team. The role may suit an individual with a technical background, with some customer-facing experience, who is now looking to develop their career with a commercial focus, at a particularly exciting stage of the company’s development.

Key Responsibilities
• Revenue generation for assigned territories (Europe) to agreed levels
• Account management of client accounts
• New business development, to grow and enhance the CML business in assigned territories (Europe)
• Arranging client meetings and attending business events
• Reporting progress through our business development infrastructure

Applicant Requirements
We envisage candidates for this exciting position will have some, if not all, of the following attributes:
• Scientific background, to BSc level or beyond
• Previous experience in a customer-facing/BD role within a chemical, pharmaceutical or life sciences environment, though candidates with a strong desire to now develop this area of your career after laboratory experience would also be considered
• Excellent communication skills
• Willingness to travel as required to develop business opportunities

Salary & Location
We offer a competitive salary and benefits, including a company pension scheme. Dependent on experience, this role may be company or home office based, though frequent attendance at the company’s sites would be expected.

Deadline for Applications: We request applications are submitted by 15th October 2017.

If you are interested in applyng for the role, please send your CV, with a covering letter to
recruitment@charnwood-molecular.com

Header for first e-shot re Cambs

Charnwood Molecular are exhibiting at this year’s 19th RSC/SCI Medicinal Chemistry Symposium, which takes place from the 10th to 13th September 2017 at Churchill College, Cambridge.

Our exhibition space is Stand O in Exhibition Marquee

Register with us now, by clicking this link:

RSC/SCI SYMPOSIUM VISITOR REGISTRATION

for the chance to win a specially selected Charnwood Brewery presentation set when you visit the Charnwood Molecular stand at the show.

IMG_3887

Charnwood Molecular will also be launching additional technical papers during this event to complement those already in its extensive library.

conference1

We are attending the forthcoming conferences in the coming months:

Charnwood Molecular Representatives: Aurelie Chabrun and Magda Foreiter
Event: SCI conference – New Synthetic Methods – Design and Application
Date: 28 September 2017
Venue: SCI, London

Charnwood Molecular Representative: Alexandre Jolibois
Event: SCI conference – Catalysis without Precious Metals
Date: 17 October 2017
Venue: SCI, London

If you would like to meet any of our representatives at these events, please email:
info@charnwood-molecular.com

chamber-awards-2017
Charnwood Molecular has been nominated as a finalist in this year’s East Midlands Chamber Business Awards in the “Small Business of the Year” category.

Finalists were announced by Chamber President, Geoff Poyzer, and Chief Executive, Scott Knowles at the Chamber President’s Summer Celebration at Thrumpton Hall, Nottingham.

This award – open to organisations employing up to 75 full-time members of staff – will go to the company that has achieved consistent growth backed by a strong financial performance.

The winner will be announced at an East Midlands gala dinner in September.

Professor Steve Allin, Managing Director of Charnwood Molecular, was delighted with the news:
“As we approach our twentieth anniversary as a company, this nomination is testament to the hard work and commitment of the entire team, past and present, at Charnwood Molecular. In that time, and fuelled by significant expansion of our global client base, we have made significant investments into our infrastructure leading to an expansion in our provision in discovery chemistry and process research services, and this nomination recognises our collective efforts in our drive to achieving excellence in our services. Regardless of the final result, we would like to thank our staff, strategic partners and clients for their continuing support.”

The business awards cover the areas of Leicestershire, Nottinghamshire and Derbyshire. The winner will be announced on 22 September 2017.

Charnwood Molecular - Tom McInally final

Charnwood Molecular is pleased to welcome Tom McInally to its group of strategic partners.

Tom has over 30 years’ experience as a medicinal chemist in the pharmaceutical industry at Fisons, Astra Charnwood and AstraZeneca in the UK. He has worked in various therapeutic areas including cardiovascular and respiratory. He led a team which integrated parallel synthesis and purification techniques into in-house LO programmes and subsequently led the chemistry team in a 6 year research collaboration with the Japanese pharmaceutical company DaiNippon Sumitomo to discover novel Toll-Like Receptor 7 agonists targeting various respiratory diseases with a lead compound entering clinical trials.

In 2011 he joined the University of Nottingham as a Business Science Fellow in Medicinal Chemistry. He has taken the lead role in teaching and mentoring 4thyr MSci project students in the principles of medicinal chemistry to enable them to undertake the GSK sponsored drug discovery project entitled “Drug discovery for Fibrotic diseases”.

Tom will work alongside the Medicinal Chemistry team at Charnwood, providing valuable insight and advice on the progress of our current projects.

Charnwood Molecular has signed a collaboration agreement with computational chemistry specialist, CCR, a Structure Based Design Consultancy headed by John King-Underwood.

By partnering with CCR, Charnwood Molecular is able to further extend its offering for effective drug discovery. This partnership will deliver contract services which help chemists design, discover and optimise small molecules against particular project targets.

CCR provides the benefits of 25 years of experience in drug discovery gained in big pharma, biotech and consultancy, encompassing many different projects and target classes. Since its conception in 2003, CCR has enabled many of its clients to achieve significant growth and success.

CCR will assist Charnwood Molecular in providing the following skills to medicinal chemistry projects:

• Molecular Modelling
• Structure Based Design
• Computational Medicinal Chemistry
• Informatics and Data Handling

Commenting on the partnership with Charnwood, John King-Underwood said: “We work with a range of partners to enhance and meet clients’ research efforts. We are delighted to be working with Charnwood Molecular at an exciting time when they are growing and working with more and more small companies needing to access first class discovery chemistry contract services. We all look forward to delivering our partnership to clients across the world.”

Dr Robin Wilkes, Director of Business Development at Charnwood Molecular stated: “CCR’s reputation, experience in tackling computational problems and proactive approach makes them the ideal collaborator for the fast-moving medicinal chemistry projects that we are increasingly working on. By adding these services and expertise to the Charnwood Molecular portfolio, we have further broadened our capabilities as a collaborative and enabling company to support drug discovery organisations.”